Do you know that Amygdala Overgrowth Occurs in the First Year of Life?
Autism, often known as autism spectrum disorder (ASD), is a group of diseases characterized by difficulty with social skills,...
Abnormal Tau Protein- A hallmark indicator of Alzheimer’s disease
Alzheimer’s disease is a neurological disorder in which the brain shrinks and the brain cells involved in the memory...
Early-Life Antibiotic Exposure, Gut Microbiome, and Neurodevelopment
Over the past few decades, there has been a dramatic increase in the incidence of childhood neurodevelopmental disorders such...
Link Between COVID-19 and Alzheimer’s Disease-Like Cognitive Impairment
Dementia-like cognitive impairment has been reported in a significant number of COVID-19 patients and long hauler patients. However, the...
FDA Approves First KRAS-Targeted Therapy for NSCLC
Lung cancer is the number one cause of cancer-related death worldwide. Each year, about 2.2 million new cases of...
Recent developments in primary hyperoxaluria treatment
Primary hyperoxaluria (PH) is a rare genetic disease in which high levels of oxalate are produced and can deposit...
Cancer vaccines in the clinic and in trials
Most vaccines are given as prophylactics, agents that protect healthy individuals before exposure to a pathogen. By contrast, therapeutic...
IpsiHand Stroke Rehab System Receives FDA Market Authorization
FDA has authorized marketing for the first-of-its-kind device to assist upper limb rehabilitation of stroke patients.1 In 2017, a...
FDA approves Qelbree, a Non-stimulant Treatment for ADHD
The FDA has approved Qelbree (SPN-812), for children aged 6 to 17 years with attention deficit hyperactivity disorder (ADHD)....
GLP-1 receptor agonists and/or DPP4 inhibitors: Diabetes drugs may lower the risk of Parkinson’s disease
Parkinson’s disease, the most common neurodegenerative movement disorder has growing prevalence with the age. Due to increasing life expectancy...